Skip Navigation

Bacterial Infections

Skip Content Marketing
  • Share this:
  • submit to facebook
  • Tweet it
  • submit to reddit
  • submit to StumbleUpon
  • submit to Google +

Workshop on the Prevention of Group A Streptococcal Diseases and their Sequelae with a Focus on Vaccine-Related Issues

March 29-30, 2004

Fernwood Building
Bethesda, MD


To develop a strategy for further clinical development of group A streptococcal vaccines and their implementation.


Time Topic Speaker
March 29th, 2004    
8:30-8:45 Welcome and introductions Goal of the workshop Fran Rubin
8:45-9:10 Overview Including historical view of vaccine development Alan Bisno
9:10-10:10 Epidemiology/ Burden of Disease Jonathan Carapetis
Anne Schuchat
10:10-10:30 Break  
10:30-12:00 Immunology/pathogenesis considerations for vaccine development including animal models Madeleine Cunningham
Malak Kotb
12:00-1:00 Lunch  
1:00-2:00 Immune correlates including laboratory considerations (serological assays) Pat Cleary
Jim Dale
2:00-3:20 Vaccine clinical trial design Karen Kotloff
Kate O’ Brien
3:20-3:40 Break  
3:40-4:20 Perspective from industry 4 presentations
4:20-5:30 FDA considerations for vaccine development Marion Gruber
Chris Mink
Norman Baylor
Time Topic Speaker
March 30th, 2004    
8:00-9:45 Implementation: US, Global, Economics Jeff Davis
Thomas Cherian
Amie Batson
9:45-10:00 Break  
10:00-10:30 Identification of obstacles for vaccine development and gaps in knowledge Sam Katz
10:45-12:30 Break out sessions  
12:30-1:30 Lunch  
1:30-2:50 Recommendations/Discussion
Breakout groups
Sam Katz
Stan Shulman
2:50-3:20 Next steps moving forward Orin Levine
3:20-3:35 Break  
3:35-3:45 Summary Alan Bisno

Workshop Publication

Prospects for a Group A Streptococcal Vaccine:
Rationale, Feasibility, and Obstacles—Report of a National
Institute of Allergy and Infectious Diseases Workshop

Clin Infect Dis. 2005 Oct 15;41(8):1150-6. Epub 2005 Sep 2.

back to top

Last Updated November 05, 2009